Drug Candidate Marketplace
Drug Candidate Marketplace lists the information of drug candidates, therapeutic targets and drug discovery technologies. Visitors can use search functions based on the interests and needs and download the list. If you have a drug candidates, therapeutic targets and drug discovery technologies that you are interested in and would like to gain more information, please contact us by clicking the inquiry button. Additional information will be provided to you.
|Date||Candidate||Mechanism of action||Indication||Route||Modality||Development stage||Note|
|10/23/19||GEM121||Modified phytic acid||Cancer||Oral||Small molecule
||Preclinical||· Demonstrated selective anti-cancer effects including apoptosis and inhibition of Akt activation.
· In vivo study using mice with adult T-cell leukemia showed reduction of the size of the cancer.
|10/23/19||GEM120||Inhibition of membrane binding of Pr55Gag||HIV||i.v.||Small molecule
||Preclinical||· Inhibited the membrane localization of Pr55Gag and stopped budding of HIV virus.
· Captures HIV in immune cells and induces apoptosis of the HIV-infected immune cells.
|10/23/19||GEM119||Inactivation of end-product of lipid peroxidation||Cerebral Infarction||i.v.||Small molecule
||Preclinical||· Showed more potent 4-hydroxynonenal - quenching activity compared with carnosine or histidine hydrazide (HH) at 30min incubation.
· GEM119 ( ip administration) rescued the hippocampal CA1 cell death of transient cerebral ischemia model of Mongolian gerbil whereas HH did not.
|10/23/19||GEM118||Suppression of TGF-b/Smad and related signaling||Systemic sclerosis||Oral||Small molecule
||Preclinical||· Inhibited phosphorylation of Smad3 and expression of Col1a2, FN1 and CTGF stimulated by TGF-b in cultured human dermal fibroblasts.
· Ameliorated bleomycin-induced skin fibrosis in both preventative and curative mouse model.
|10/16/19||GEM117||Induction of apoptosis in adipocyte||Liposysis, non-surgical fat reduction, Diabesity,||Refer to Note||Small molecule
· GEM117 specifically induce apoptosis on local injection site adipocyte · Phase 1 showed great safety without drug related SAE in 40 healthy volunteers · In pre-clinical study
- Better efficacy on local fat reduction and less side effects that surpass the current surgical liposuction and other non-surgical products.
- Has benefit effects on lipid and glucose metabolism and improves the indicator of diabetes
|10/16/19||GEM116||Increase in lipolysis, fat and energy metabolism||Obesity, Diabesity, NAFLD/NASH||Oral||Small molecule
||Phase 2||· GEM116 demostrated the saftest profile in its clinical phase 2 study with more than 200 patients without any drug related AE or SAE and potentially lower CVD risk seen by other competitors in the market
· Around 30% of subjects lost at least 5% body weight in 12 weeks, GEM116 shows around 5% body fat lost, lower TC by around 12mg/dL, and lower LDL by around 6 mg/dL
·Pre-clinical study shows GEM116 has the potential to treat NAFLD/NASH via reducing liver fibrosis by aroud 40%
|10/16/19||GEM115||Trastuzumab biosimilar-ADC||HER2-positive metastatic breast cancer||i.v.||Antibody
||Phase 1||Conjugate of trastuzumab biosimilar and DM-1. The profiles of trastuzumab of GEM115 and GEM115 are similar to Herceptin and Kadcyla, respectively, in peptide mapping, receptor binding affinity, inhibition of cell proliferation, ADCC activities, in vivo xenograft mouse model, PK etc.
Potential Indication: Early Breast Cancer (adjuvant)
|10/16/19||GEM114||Ophthalmic formulation of GEM113||wet AMD||intravetreal||Antibody
||Phase 1||GEM114 mainly distributed in retina, vitreous body and aqueous humor after intravetreal injection in animals.
Potential Indication: Diabetic Macular Edema; Myopic Choroidal Neovascularization (mCNV); Retinal Vein Occlusion (RVO); Diabetic Retinopathy (DR)
|10/16/19||GEM113||Bevacizumab biosimilar||Non-Squamous NSCLC||i.v.||Antibody
||Phase 3||The profile of GEM113 is similar to Avastin, in peptide mapping, receptor binding affinity, inhibition of cell proliferation, in vivo xenograft mouse model, PK etc.
Potential Indication: Metastatic Coloerectal Cancer; Recurrent Giloblastoma; Metastatic Renal Cell Carcinoma; Persistent Recurrent or Metastatic Cervical Cancer; Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
|10/04/19||GEM065||Refer to Note||Refer to Note||Infusion||Protein
||Refer to Note||Mechanism of action:
Fucosylation of CAR-T cell and TCR-T cells to improve homing to tumors, increased intra-tumor penetration and killing of cancer cells. Potential for enabling CAR-T cell therapies to achieve higher response rates for treatment of blood cancers and also work for treatment of solid tumors
Lymphoma, leukemia, melanoma, lung and breast cancers are initial indications
Preclinical; Human safety and efficacy observed in stem cell transplantation
Ex-vivo fucosylation kit using proprietary recombinant fucosyl-transferase enzymes aimed at improving efficacy, safety and cost of care for T-cell therapy not only for treatment of blood cancers but also importantly, enabling CAR-T cell therapy to work in the treatment of solid tumors . Similar technology as in GEM036 for hematopoietic stem cell therapy, but a different fucosyl-transferase is used. Fucosylation enhances homing and intra-tumor penetration of CAR-T, TCR-T, TIL/CTL cells for improved tumor killing. Fucosylation does not affect healthy tissues.